3 Multi-Specialty Hospital Network, Children’s Hospital Chain and Single-Use Medical Device Maker Stocks With a Strong Future Roadmap: Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure
- October 23, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure: ROE of 10.4% to 16.9% and FY22 to FY26 revenue CAGR of 15.2% to 20.4%. Prices as of 22 Oct 2026.
Quick Answer
The three hospital network and medical device stocks to watch are Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure. Their return on equity ranges from 10.4% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.2% to 20.4%. Rainbow Children’s Medicare has the highest return on equity at 16.9%, while Max Healthcare Institute has the fastest revenue growth at 20.4% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Hospital network and medical device stocks let investors follow companies that deliver care and supply the products used in it. Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure cover a multi-specialty hospital network, a children’s hospital chain and a maker of single-use medical devices.
This list covers three hospital network and medical device stocks with complete current figures: Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Hospital Network and Medical Device Stocks?
Hospital network and medical device stocks are listed companies that run hospitals or manufacture devices such as infusion sets and catheters. Their earnings depend on bed additions, occupancy, procedure mix and export orders.
Hospital Network and Medical Device Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Max Healthcare Institute | 819.9 | 80,717 | 55.4 | 59.6 | 13.4 | 0.32 |
| Rainbow Children’s Medicare | 1,209 | 12,554 | 43.2 | 59.6 | 16.9 | 0.54 |
| Poly Medicure | 1,448.9 | 15,721 | 50.2 | 59.6 | 10.4 | 0.11 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing hospital network and medical device stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital network and medical device stocks can use the coming numbers to test whether growth is holding.
Why Do Hospital Network and Medical Device Stocks Have a Strong Roadmap in India?
Hospital network and medical device stocks have a strong roadmap in India because rising incomes, wider insurance cover and a growing preference for organised care keep adding patients and procedures.
- Bed additions. New hospital capacity serves growing patient demand.
- Specialised care. Oncology, cardiac and paediatric services earn better revenue per patient.
- Device exports. Single-use devices find buyers in many countries.
Why Max Healthcare Institute Features Among These Hospital Network and Medical Device Stocks
Among the hospital network and medical device stocks on this list, Max Healthcare Institute runs a large network of multi-specialty hospitals concentrated in Delhi NCR, Punjab, Uttarakhand and Maharashtra, with a strong presence in oncology, cardiac sciences, neurosciences and orthopaedics.
Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%.
In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P/E of 55.4, below the industry P/E of 59.6.
Roadmap: The roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.
What to watch: Track how quickly new beds reach stable occupancy and whether average revenue per occupied bed keeps rising.
Why Rainbow Children’s Medicare Features Among These Hospital Network and Medical Device Stocks
Among the hospital network company shares on this list, Rainbow Children’s Medicare operates paediatric, neonatal and maternity hospitals under the Rainbow Children’s Hospital and BirthRight by Rainbow brands, with clusters in Hyderabad, Bengaluru, Chennai and Delhi NCR.
In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore. Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%.
Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%. The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6.
Roadmap: The company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women’s healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.
What to watch: Monitor how fast new clusters in Delhi NCR and other regions reach breakeven.
Why Poly Medicure Features Among These Hospital Network and Medical Device Stocks
Among the three companies on this list, Poly Medicure makes single-use medical devices such as infusion sets, syringes, catheters, blood management products and dialysis consumables, and it exports to many countries.
The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6.
Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore.
Roadmap: The company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
What to watch: Track export growth, new product approvals and plant capacity use.
Max Healthcare Institute vs Rainbow Children’s Medicare vs Poly Medicure on Key Financials
The table below sets the three hospital network and medical device stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Max Healthcare Institute | 4,059 | 8,536 | 20.4% | 1,442 | 16.9% |
| Rainbow Children’s Medicare | 993 | 1,747 | 15.2% | 282 | 16.1% |
| Poly Medicure | 961 | 1,995 | 20.0% | 321 | 16.1% |
Rainbow Children’s Medicare posts the highest return on equity in this group at 16.9%. Max Healthcare Institute combines the largest FY26 revenue at Rs 8,536 crore with the fastest revenue growth, a 20.4% compound annual rate. A useful habit with hospital network and medical device stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several single-use device maker stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Max Healthcare Institute | 2,064 | 2,407 | 16.6% |
| Rainbow Children’s Medicare | 373 | 483 | 29.4% |
| Poly Medicure | 445 | 559 | 25.5% |
Key Risks to Check Before Investing in Hospital Network and Medical Device Stocks
Every theme carries risks that deserve a check before any decision. For these hospital network and medical device stocks, the main points are: Long-term hospital network company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Ramp-up timing. New hospitals take time to reach stable occupancy.
- Doctor availability. Experienced doctors are central to growth and hard to attract.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter hospital network and medical device stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Hospital Network and Medical Device Stocks
Hospital network and medical device stocks reward investors who follow bed additions, occupancy and export orders together. Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure each have a clear plan to widen their reach. Based on the 22 October 2026 close, Max Healthcare Institute trades at Rs 819.9, Rainbow Children’s Medicare at Rs 1,209 and Poly Medicure at Rs 1,448.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these hospital network and medical device stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track hospital network and medical device stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are hospital network and medical device stocks?
Ans. Hospital network and medical device stocks are listed companies that run hospitals or manufacture devices such as infusion sets and catheters. Their earnings depend on bed additions, occupancy, procedure mix and export orders. This list looks at three of them, Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which hospital network and medical device stocks are covered in this list?
Ans. This list covers Max Healthcare Institute, Rainbow Children’s Medicare and Poly Medicure. Based on the 22 October 2026 close, Max Healthcare Institute traded at Rs 819.9, Rainbow Children’s Medicare at Rs 1,209 and Poly Medicure at Rs 1,448.9. Their return on equity ranges from 10.4% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.2% to 20.4%.
Why do hospital network and medical device stocks have a strong future roadmap in India?
Ans. Hospital network and medical device stocks have a strong roadmap in India because rising incomes, wider insurance cover and a growing preference for organised care keep adding patients and procedures. The main drivers are as follows. Bed additions. New hospital capacity serves growing patient demand. Specialised care. Oncology, cardiac and paediatric services earn better revenue per patient. Device exports. Single-use devices find buyers in many countries. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Max Healthcare Institute performed financially?
Ans. Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%. In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P/E of 55.4, below the industry P/E of 59.6. Looking ahead, the roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.
How has Rainbow Children’s Medicare performed financially?
Ans. Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6. Looking ahead, the company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women’s healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.
How has Poly Medicure performed financially?
Ans. Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6. Looking ahead, the company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
What risks should investors check before buying hospital network and medical device stocks?
Ans. Investors should check a few risks before buying hospital network and medical device stocks. Ramp-up timing. New hospitals take time to reach stable occupancy. Doctor availability. Experienced doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of hospital network and medical device stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
